2019 CMCR Symposium

On Friday, October 18, 2019 the Center for Medicinal Cannabis Research (CMCR) held a one-day symposium celebrating the pioneers and exploring the progress, promise, and challenges of medicinal cannabis research. Click here to view an archive of the event broadcast.

Current CMCR studies

Current studies examine the effects of cannabis on pain and the potential benefits of CBD tinctures in the treatment of autistic children as well as public safety issues surrounding the use of cannabis and cannabinoids. The CMCR has recently funded 5 new research studies and as recruitment begins, the details of those studies can be found here.

CMCR announces $3M in new research grants to California investigators

The Center for Medicinal Cannabis Research (CMCR) at UC San Diego has been a leader in medical marijuana research since 2000. In the past CMCR has allocated funds to investigators in California to conduct some of the first proof of principle clinical trials of cannabis in neuropathic pain and multiple sclerosis. Learn more about the studies to be funded.

  • All
  • Announcements
  • Current Studies
  • Information
  • News
  • Presentations
  • Publications
  • Studies
  • Symposia
  • Default
  • Title
  • Date
  • Random
load more hold SHIFT key to load all load all

PI: Thomas Marcotte, Ph.D. & Barth Wilsey, M.D.

The major objective of the present study is to demonstrate an analgesic response to oral and/or inhaled cannabis in patients with neuropathic low back pain.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain

PROJECT TYPE: Clinical Study

STATUS: Active

ABSTRACT:

This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.5% Δ9-THC, or placebo.

The primary outcome will be a pain intensity numerical rating scale bordered by 0=no pain and 10=worst possible pain. As a major goal in the development of cannabinoid-based medications is the separation of pain relief from side-effects, numerous other assessments will also be performed. Neuropsychological testing with the Digit Symbol Modalities Test (attention), the Hopkins Verbal Learning Test (learning and memory) and the Grooved Pegboard Test (psychomotor performance) will be performed. In addition, driving simulation will be completed to assess the effect of study medications on this important component of everyday life. Subjective effects will be evaluated with the Marijuana subscale (M-scale) from the Addiction Research Center Inventory to evaluate cannabis intoxication. In addition, questions that include measures of 'high' or 'liking' will be analyzed.

The degree of pain relief will then be compared with the adverse consequences of cannabis to assess the risk-benefit ratio of dronabinol and 3.5% Δ9-THC.

 

Interested in participating? Click here to contact us.